Disease/Infection News

RSS

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

Honduras becomes first LAC country to launch national plan to combat NTDs

"A major milestone was achieved on April 12, when Honduras became the first country in the Latin America and the Caribbean (LAC) region to officially launch an integrated national plan to combat neglected tropical diseases (NTDs)," the the Global Network for Neglected Tropical Diseases' "End the Neglect" blog reports.

20 Apr 2012

Researchers examine impact of user experience with topical vaginal gels against HIV

Are women willing to use a vaginal gel to protect themselves against HIV infection? Researchers at The Miriam Hospital say that is the million dollar question when it comes to developing products known as microbicides that can prevent the sexual transmission of HIV.

20 Apr 2012

Study determines importance of bacterial infections in cirrhosis

A South African study presented today determines the importance of bacterial infections, which commonly occur in cirrhosis and can alter the natural history of the condition, possibly leading to loss of liver function and decompensation. It is now recognised that many infections in cirrhotic patients result from bacterial translocation (BT) from the intestine.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Blog examines potential effects of AIDS funding cuts, shortfalls

The Center for Global Health Policy's "Science Speaks" blog examines a memorandum from the Foundation for AIDS Research (amfAR), distributed "to a targeted list of congressional leaders with jurisdiction over PEPFAR or the appropriations committees that fund it," "that makes the case for continued funding for the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program at least at fiscal year (FY) 2012 funding levels."

20 Apr 2012

Access to family planning services important for adolescent women

In a Huffington Post "Global Motherhood" opinion piece, UNFPA Executive Director Babatunde Osotimehin writes, "It warms my heart to see that safe motherhood and women's reproductive health are finally being recognized as important development issues," but "millions of women in developing countries still lack even the most basic care during pregnancy," leading to maternal death and injury and hundreds of millions of women lack access to family planning services, including modern contraceptives.

20 Apr 2012

Guardian blog examines potential impact of Global Fund reform on organization's future

In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

WHO releases guidance on couples testing, counseling, including ART for discordant couples

The WHO on Wednesday released its new 54-page "Guidance on couples HIV testing and counselling, including antiretroviral therapy (ART) for treatment and prevention in serodiscordant couples: Recommendations for a public health approach," according to the Center for Global Health Policy's "Science Speaks" blog.

20 Apr 2012

NSABB calls for global guidelines for conducting, communicating research involving dangerous pathogens

NewScientist reports on the U.S. National Science Advisory Board for Biosecurity's (NSABB) recommendation that revised versions of two controversial studies on H5N1 avian flu be published in scientific journals, reversing its previous recommendation that the studies only be published if certain details were withheld. According to the news service, dissent among the board members over the issue has prompted the committee to "propose talks to draft global guidelines for doing and communicating work involving dangerous pathogens."

20 Apr 2012

U.S. Global AIDS Coordinator tells GlobalPost State Department reviewing nearly $1.5B in unused PEPFAR funding

Prompted by an inquiry from GlobalPost, U.S. officials have said the Obama administration called for a $550 million reduction -- an 11 percent cut -- for its global AIDS program in its FY 2013 budget request because the "government didn't need more money because there has been nearly $1.5 billion stuck in the pipeline for 18 months or more," GlobalPost reports.

20 Apr 2012

Entire HCV lifecycle can be recapitulated in murine cells

A US study presented today at The International Liver CongressTM 2012 demonstrates that the entire HCV lifecycle can be recapitulated in murine cells, implying that HCV permissive mouse models could soon be developed.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

Babies rarely became ill from MRSA infections: Study

The need to swab the noses of pregnant women and newborns for the presence of MRSA (methicillin-resistant Staphylococcus aureus) may be unfounded, according to a Vanderbilt study now available online and published in the May issue of Pediatrics.

20 Apr 2012

BuruliVac project getting closer to a vaccine

During a meeting in Lisbon, the partners of the BuruliVac research consortium found the project to be running smoothly, and getting closer to a vaccine against Buruli ulcer, a disfiguring and mutilating disease that causes a lot of suffering and now is difficult to treat. Several vaccine candidates work well in mice and are ready for further testing on blood of patients; one is ready for testing in mice.

19 Apr 2012

EASL publishes new clinical practice guideline on ALD

EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

19 Apr 2012

Two studies show true impact of liver disease across Europe

Two studies presented at the International Liver Congress- 2012 show the true impact that liver disease has across Europe. One highlights the financial cost of liver disease to the community and the second highlights the high mortality rates associated with cirrhosis.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

Disease/Infection News

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

Honduras becomes first LAC country to launch national plan to combat NTDs

Researchers examine impact of user experience with topical vaginal gels against HIV

Study determines importance of bacterial infections in cirrhosis

New data provides hope for HCV non-responders

New data shows consolidation of interferon-free revolution in HCV treatment

Blog examines potential effects of AIDS funding cuts, shortfalls

Access to family planning services important for adolescent women

Guardian blog examines potential impact of Global Fund reform on organization's future

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

WHO releases guidance on couples testing, counseling, including ART for discordant couples

NSABB calls for global guidelines for conducting, communicating research involving dangerous pathogens

U.S. Global AIDS Coordinator tells GlobalPost State Department reviewing nearly $1.5B in unused PEPFAR funding

Entire HCV lifecycle can be recapitulated in murine cells

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Babies rarely became ill from MRSA infections: Study

BuruliVac project getting closer to a vaccine

EASL publishes new clinical practice guideline on ALD

Two studies show true impact of liver disease across Europe

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News